MedTrace Logo

The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa

NCT03414112 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-02-11

No results posted yet for this study

Summary

This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli as well as eating behavior in a test meal paradigm.

Conditions

  • Anorexia Nervosa

Interventions

BIOLOGICAL

Intranasal oxytocin

oxytocin is a peptide hormone that influences social affiliation

Sponsors & Collaborators

Principal Investigators

  • Carol B Peterson, PhD · University of Minnesota

  • Ann F Haynos, PhD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2021-04-30
Completion
2021-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414112 on ClinicalTrials.gov